Journal Information
Vol. 37. Num. 6.June 2018
Pages 457-548
Share
Share
Download PDF
More article options
Visits
211
Vol. 37. Num. 6.June 2018
Pages 457-548
Editorial comment
DOI: 10.1016/j.repce.2018.06.001
Open Access
Fabry disease: Something cardiologists must always bear in mind
Doença de Fabry – um lembrete obrigatório para os cardiologistas!
Visits
211
Nuno Bettencourt
Unidade de Investigação Cardiovascular, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Related content
Rev Port Cardiol 2018;37:457-6610.1016/j.repce.2018.03.015
Dulce Brito, Nuno Cardim, Luís Rocha Lopes, Adriana Belo, Jorge Mimoso, Lino Gonçalves, Hugo Madeira
This item has received
211
Visits

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

In this issue of the Journal, Brito et al. present a very interesting work1 based on data extracted from the Portuguese Registry of Hypertrophic Cardiomyopathy.2

Focusing on a non-mandatory question from this registry, concerning the exclusion of Anderson-Fabry disease in the differential diagnosis, the authors concluded that this entity is seldom studied in the workup of patients with unexplained left ventricular hypertrophy. According to their data, Fabry disease was recorded as excluded in only 27% of the patients included in the registry. Alpha-galactosidase A (α-Gal A) activity was assessed in 18% and GLA gene testing was only performed in 23% of cases. Among patients with potential red flags for Fabry disease (including concentric left ventricular hypertrophy, short or prolonged PR interval, intraventricular conduction disturbances or bradyarrhythmias requiring pacemaker implantation), fewer than half (47%) underwent specific tests (GLA gene testing and/or α-Gal A activity).

These results are even more striking if we note that only cardiology departments were included in the registry, which is totally voluntary, and that inclusion was not sequential. Bearing this in mind, there is a high probability of bias toward the inclusion of better-studied patients and a higher participation of centers with better overall performance in cardiomyopathies. This means that in real-world practice the rates of Fabry disease exclusion in these patients are probably even lower than reported here.

Portugal has some of the largest series of Fabry disease patients in Europe, and these numbers are mainly due to the systematic diagnostic workup performed in reference centers for lysosomal storage diseases.3–6 Although some geographic distribution patterns are clearly discernible, as can be expected from an X-linked genetic disease, it is essential to maintain general awareness of this disease, for which specific therapies are available that can modify prognosis. Since cardiac involvement is frequent and is sometimes the primary or sole manifestation of Fabry disease, all cardiologists should be constantly on the alert for the possibility of Fabry disease in the study of unexplained left ventricular hypertrophy. Early diagnosis and, if appropriate, initiation of enzyme replacement therapy can change the course of this disease and may improve both symptoms and prognosis. Furthermore, identification of an index case can help identify relatives affected by disease, who may also benefit from diagnostic workup, structured follow-up and early initiation of therapy, if indicated.

In an era of advanced imaging and readily available genetic testing, efforts should be made to ensure that red flags for Fabry disease in patients with left ventricular hypertrophy are identified and to encourage the use of dedicated tools for its exclusion. This paper has a clear message for all cardiologists: Fabry disease is something that must always be borne in mind in the study of patients with unexplained left ventricular hypertrophy.

Conflicts of interest

The author has no conflicts of interest to declare.

References
[1]
D. Brito,N. Cardim,L.R. Lopes
Awareness of Fabry disease in cardiology: a gap to be filled
Rev Port Cardiol, 37 (2018), pp. 457-466 http://dx.doi.org/10.1016/j.repc.2018.03.010
[2]
N. Cardim,D. Brito,L.R. Lopes
The Portuguese Registry of Hypertrophic Cardiomyopathy: overall results
Rev Port Cardiol, 37 (2018), pp. 1-10 http://dx.doi.org/10.1016/j.repc.2017.08.005
[3]
P. Aguiar,O. Azevedo,R. Pinto
Biomarkers of myocardial fibrosis: revealing the natural history of fibrogenesis in Fabry disease cardiomyopathy
J Am Heart Assoc, 7 (2018, March), http://dx.doi.org/10.1161/JAHA.117.007124
[4]
J. Rodrigues,O. Azevedo,N. Sousa
Inner ear involvement in fabry disease: clinical and audiometric evaluation of a large cohort of patients followed in a reference centre
Eur J Med Genet, (2018, January),
pii: S1769-7212(17)30574-8
[5]
D. Brito,G. Miltenberger-Miltenyi,O. Moldovan
Cardiac Anderson-Fabry disease: lessons from a 25-year-follow up
Rev Port Cardiol, 33 (2014, April), pp. 247 http://dx.doi.org/10.1016/j.repc.2013.10.014
e1–7
[6]
I. Beirão,A. Cabrita,M. Torres
Is it Fabry disease? Diagnostic and follow-up approach
Acta Med Port, 29 (2016), pp. 85-87
Idiomas
Portuguese Journal of Cardiology

Subscribe to our Newsletter

Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos